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ALK, activin receptor-like kinase 
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ARB, Ang II type 1 receptor blockers 
AT1R and AT2R, Ang II type 1 and type 2 receptor 
BMPRI and BMPRII, BMP type I and type II receptor 
CYP11B2, P450aldo gene 
ECD, extracellular domain 
ERK, extracellular signal-regulated kinase 
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StAR, steroidogenic acute regulatory protein 
TGF-β, transforming growth factor-β 
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ABSTRACT 
 
Circulating aldosterone concentrations occasionally increase after initial 
suppression with angiotensin II (Ang II) converting enzyme inhibitors or Ang II type 1 
receptor (AT1R) blockers (ARB), a phenomenon referred to as “aldosterone 
breakthrough”.  However, the underlying mechanism causing the aldosterone 
breakthrough remains unknown.  Here we investigated whether aldosterone 
breakthrough occurs in human adrenocortical H295R cells in vitro.  We recently 
reported that BMP-6, which is expressed in adrenocortical cells, enhances Ang II- but 
not potassium-induced aldosterone production in human adrenocortical cells.  
Accordingly, we examined the roles of BMP-6 in aldosterone breakthrough induced by 
long-term treatment with ARB.  Ang II stimulated aldosterone production by 
adrenocortical cells.  This Ang II stimulation was blocked by an ARB, candesartan.  
Interestingly, the candesartan effects on Ang II-induced aldosterone synthesis and 
CYP11B2 expression were attenuated in a course of candesartan treatment for 15 days.  
The impairment of candesartan effects on Ang II-induced aldosterone production was 
also observed in Ang II- or candesartan-pretreated cells.  Levels of AT1R mRNA were 
not changed by chronic candesartan treatment.  However, BMP-6 enhancement of Ang 
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II-induced ERK1/2 signaling was resistant to candesartan.  The BMP-6-induced 
Smad1,5,8 phosphorylation and BRE-Luc activity was augmented in the presence of 
Ang II and candesartan in the chronic phase.  Chronic Ang II exposure decreased 
cellular expression levels of BMP-6 and its receptors ALK-2 and ActRII mRNAs.  
Co-treatment with candesartan reversed the inhibitory effects of Ang II on the 
expression levels of these mRNAs.  The breakthrough phenomenon was attenuated by 
neutralization of endogenous BMP-6 and ALK-2.  Collectively, these data suggest that 
changes in BMP-6 availability and response may be involved in the occurrence of 
cellular escape from aldosterone suppression under chronic treatment with ARB. 
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INTRODUCTION 
 
Production of aldosterone occurs in the adrenal glomerulosa, which is regulated 
primarily by angiotensin II (Ang II) and potassium and, to a lesser degree, 
adrenocorticotropin (ACTH) (1, 2).  In the presence of these aldosterone stimulators, 
steroidogenesis in the adrenal cortex is further governed by local autocrine and/or 
paracrine factors (3).  We previously reported the presence of a functional bone 
morphogenetic protein (BMP) and activin system complete with ligands including 
BMP-6, activins and their receptors in the human adrenocortical cell line, H295R (4).  
BMPs were originally identified as the active components in bone extracts capable of 
inducing bone formation at ectopic sites.  A variety of physiological BMP actions in 
many endocrine tissues including the ovary (5-7), pituitary (8, 9), thyroid (10) and 
adrenal (4, 11) have been elucidated to date. 
In human H295R adrenocortical cells, BMP-6 augments Ang II-induced 
aldosterone production and activin regulates ACTH-dependent aldosterone production 
(4).  Further investigation demonstrated that BMP-6 activated Ang II-induced 
CYP11B2 transcription and aldosterone production; in contrast, BMP-6 had no effect 
on potassium-induced aldosterone production (12).  Based on the established role of 
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the endogenous BMP system in Ang II-induced aldosterone production (12), we 
hypothesized that BMP-6 actions in adrenocortical cells may be involved in 
“aldosterone breakthrough”. 
Clinical trials have established that plasma aldosterone levels occasionally 
increase after an initial decline in some patients over the course of long-term therapy 
with angiotensin-converting enzyme (ACE) inhibitors and/or Ang II type 1 receptor 
(AT1R) blocker (ARB).  Aldosterone breakthrough is a phenomenon where circulating 
aldosterone concentrations increase above pretreated levels after long-term therapy with 
ACE inhibitors (13, 14) or ARB (15).  This phenomenon, termed ‘aldosterone escape’ 
or ‘aldosterone breakthrough’, could have important clinical consequences since 
increased aldosterone in a high salt state may facilitate cardiovascular and renal 
damages in hypertensive patients (16, 17).  Involvement of various in vivo factors such 
as ACTH, electrolytes, endothelins and Ang II type 2 receptor (AT2R) actions (15, 18) 
have been proposed to explain this breakthrough phenomenon; however, the detailed 
underlying mechanism remains unknown. 
In the present study, we hypothesized that local BMP-6 actions in 
adrenocortical cells may be involved in the mechanism of aldosterone breakthrough.  
To elucidate the underlying cellular mechanism by which aldosterone breakthrough 
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phenomenon occurs in the process of chronic AT1R blockade of human adrenocortical 
cells, we examined the possible role of BMP-6 in aldosterone breakthrough occurring 
with long-term ARB therapy in in vitro human adrenocortical H295R cells. 
 
MATERIALS AND METHODS 
 
Reagents and Supplies 
A 1:1 mixture of Dulbecco’s Modified Eagle’s Medium/Ham’s F-12 medium 
(DMEM/F12), penicillin-streptomycin solution, and Ang II acetate salt were purchased 
from Sigma-Aldrich Co. Ltd. (St. Louis, MO).  Insulin-transferrin-sodium selenite plus 
(ITS+) was from BD Falcon (Bedford, MA).  Recombinant human BMP-6, 
extracellular domains (ECDs) which lack transmembrane and intracellular domains of 
ALK-2 and ALK-6 (19), anti-human BMP-6 polyclonal antibody, and normal goat 
antibody were from R&D Systems (Minneapolis, MN).  Candesaran, CV-11974 was 
provided from Takeda Chemical Industries (Osaka, Japan).  Adult male spontaneously 
hypertensive rats (SHR) and Wistar-Kyoto (WKY) rats were purchased from 
Charles-River (Wilmington, MA).  The animal protocols were approved by Okayama 
University Institutional Animal Care and Use Committee.  The plasmid of BRE-Luc 
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containing a BMP-responsive element fused to the firefly luciferase reporter gene was 
kindly provided from Drs. Tetsuro Watabe and Kohei Miyazono, Tokyo University, 
Japan. 
 
Cell culture and aldosterone assay 
The NCI-H295R human adrenocortical cell line was obtained from American Type 
Culture Collection (Manassas, VA).  H295R cells were cultured in DMEM/F12 
medium containing 4 mM of potassium, 10% fetal calf serum (FCS), ITS+ supplements 
and antibiotics (penicillin and streptomycin).  The cells were cultured at 37°C under a 
humid atmosphere of 95% air/5% CO2 as previously reported (4, 12).  To assess the 
effect of treatments on aldosterone secretion, monolayered cells (4 × 104 viable cells) 
were precultured in 96-well human fibronectin-coated plates (Biocoat, BD-Falcon).  
After 48-h culture, the medium was replaced with fresh medium containing 4 mM of 
potassium and 1% FCS with or without various combinations of Ang II, candesartan, 
BMP-6, ALK-2- or ALK-6-ECDs, and anti-BMP-6 or control IgG at indicated 
concentrations.  H295R cells were then cultured for indicated periods and the 
accumulated levels of aldosterone in the conditioned media were determined by 
radioimmunoassay (SPAC-S aldosterone, TFB Co., Tokyo, Japan). 
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RNA extraction, RT-PCR and quantitative real-time PCR analysis 
H295R cells (1 × 106 viable cells) were grown in 6-well plates and the medium was 
replaced with fresh DMEM/F12 containing 4 mM of potassium and 1% FCS.  The 
cells were treated with Ang II, aldosterone, or combinations of the reagents including 
candesartan and BMP-6 as indicated concentrations.  After culture for indicated 
periods, the medium was removed and total cellular RNA was extracted by 
isothiocyanate-acidphenol-chloroform methods using TRIzol (Invitrogen Corp., 
Carlsbad, CA) and quantified by measuring absorbance at 260 nm and stored at -80°C 
until assay.  Oligonucleotides used for RT-PCR were custom-ordered from Invitrogen 
Corp.  PCR primer pairs were selected from different exons of the corresponding 
genes to discriminate PCR products that might arise from possible chromosome DNA 
contaminants.  In brief, the extracted RNA (1 µg) was subjected to a RT reaction using 
First-Strand cDNA Synthesis System (Invitrogen Corp.) with random hexamer (2 
ng/µl), reverse transcriptase (200 U) and deoxynucleotide triphosphate (dNTP; 0.5 mM).  
The primer settings for StAR, P450scc, CYP11B2, BMP-6 (4, 12, 20), ALK-2, ALK-3, 
ActRII, Smad1, Smad4, Smad5, and a house-keeping gene, ribosomal protein L19 
(RPL19) (8, 21), were followed by our earlier reports.  For the quantification, real-time 
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PCR was performed using LightCycler-FastStart DNA master SYBR Green I system 
(Roche Diagnostic Co., Tokyo, Japan) under the condition of annealing at 60°C with 4 
mM MgCl2 following the manufacture’s protocol.  Accumulated levels of fluorescence 
were analyzed by second-derivative method after the melting-curve analysis and then 
the expression levels of target gene transcripts were standardized by RPL19 level in 
each sample. 
 
Transient transfection and luciferase assay 
After 24-h preculture in 12-well human fibronectin-coated plates (Biocoat, 
BD-Falcon), H295R cells (~60% confluency) were transiently transfected with 500 ng 
of each luciferase reporter plasmid (BRE-Luc) and 0.1 µg of 
cytomegalovirus-β-galactosidase plasmid (pCMV-β-gal) using FuGENE 6 (Roche 
Molecular Biochemicals, Indianapolis, IN) after 1-, 7- and 15-day pretreatment with a 
combination of Ang II and candesartan.  The cells were then treated with BMP-6 at 
indicated concentrations in DMEM/F12 containing 4 mM of potassium and 1% FCS for 
24 h.  The cells were washed with PBS and lysed with Cell Culture Lysis Reagent 
(TOYOBO, Osaka, Japan).  Luciferase activity and β-galactosidase (β-gal) activity of 
the cell lysate were measured by luminometer as we previously reported (22).  The 
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data were shown as the ratio of luciferase to β-gal activity. 
 
Western immunoblot analysis 
Cells (1 × 106 viable cells) were seeded in 12-well human fibronectin-coated plates 
(Biocoat, BD-Falcon) in DMEM/F12.  After 24-h preculture with serum-free 
conditions containing 4 mM of potassium, indicated concentrations of BMP-6, Ang II 
and candesartan were added to the culture media.  Following stimulation by hormones 
and growth factors in the indicated time course, cells were solubilized in 100 µl RIPA 
lysis buffer (Upstate Biotechnology, Charlottesville, VA) containing 1 mM Na3VO4, 1 
mM NaF, 2% SDS and 4% β-mercaptoethanol as we have earlier reported (10).  The 
cell lysates were then subjected to SDS-PAGE immunoblotting analysis using 
anti-phospho-, anti-total-extracellular signal-regulated kinase (ERK) 1/2 MAP kinases 
antibodies and anti-phospho-Smad1/5/8 antibody (Cell signaling Technology, Inc., 
Beverly, MA). 
 
Immunofluorescence microscopy 
For immunofluorescence study, H295R cells were precultured in serum-free 
DMEM/F12 containing 4 mM of potassium using chamber slides (Nalge Nunc Int., 
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Naperville, IL).  Cells at ~50% confluency were pretreated with a combination of Ang 
II and candesartan for 1 h and then treated with BMP-6 (100 ng/ml) for 1 h.  Cells 
were then fixed with 4% formaldehyde in PBS, permeabilized with 0.5% Triton X-100 
in PBS at room temperature, and washed three times with PBS.  The cells were then 
incubated with anti-phospho-Smad1,5,8 antibody (Cell signaling Technology, Inc.) for 
1 h and washed three times with PBS.  Cells were then incubated with Alexa Fluor 
488 anti-rabbit IgG (Invitrogen Corp.) in humidified chamber for 1 h and washed with 
PBS, and then stained cells were visualized under fluorescent microscope. 
 
Immunohistochemistry study 
For the immunohistochemical analyses, 4 µm-thick sections of formalin-fixed and 
paraffin-embedded adrenal tissues were dewaxed and rehydrated, and antigen retrieval 
was performed by heating for 15 min in a 10 mM citrate buffer at pH 6.0.  The 
sections were reacted with gout polyclonal antibody for BMP-6 (R&D Systems) diluted 
at 10 µg/ml for 16 h at 4°C, and then were subsequently stained using the universal 
immuno-peroxidase polymer method with Histofine staining kit (Nichirei Corp., Tokyo, 
Japan) according to the manufacturer’s protocol.  Positive reaction was visualized with 
3,3'-diaminobenzidine tetrahydrochloride, followed by counterstaining with 
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hematoxylin.  For negative controls, normal goat antibody was used instead of primary 
antibodies, and no specific immunoreactivity was detected in these sections. 
 
Statistical analysis 
All results are shown as mean ± SEM of data from at least three separate experiments, 
each performed with triplicate samples.  Differences between groups were analyzed 
for statistical significance using ANOVA with Fisher’s protected least significant 
difference (PLSD) test (StatView 5.0 software, Abacus Concepts, Inc., Berkeley, CA).  
P values < 0.05 were accepted as statistically significant. 
 
RESULTS 
 
The in vitro effects of an ARB, candesartan on Ang II-induced aldosterone 
production were examined using human adrenocortical H295R cells.  Aldosterone 
levels were measured in the medium accumulated during the indicated culture 
conditions.  As shown in Fig. 1A, Ang II (1 to 30 nM) stimulated aldosterone 
production for 24-h culture.  Ang II-induced aldosterone production for 24 h was 
blocked by candesartan (0.3 to 10 nM) in a dose-dependent manner.  Based on this 
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result, 1.0 nM candesartan was selected as the IC50 value for Ang II (10 nM)-induced 
aldosoterone levels in order to examine long-term effects of candesartan on Ang 
II-induced aldosterone accumulation in the medium by H295R cells.  The time-course 
reduction of Ang II-induced aldosterone accumulation by candesartan treatment was 
demonstrated in Fig. 1B.  Accumulated aldosterone concentration attained 3 to 4 nM 
in our culture conditions for 15 days.  Candesartan treatment inhibited Ang II-induced 
aldosterone levels by 50% to 60%, an effect that was sustained for up to 10 days in 
culture conditions.  After 13- to 15-day treatment with candesartan, the levels of 
aldosterone synthesis rebounded to 80% to 85% of Ang II-induced aldosterone levels 
(Fig. 1B).  
To further investigate the dynamics of the impairment of aldosterone 
suppression by long-term candesartan action, 24-h production of aldosterone was 
evaluated in the cells pretreated with Ang II and candesartan for 3 days.  During the 
culture period, culture medium was completely changed into fresh media containing a 
steady concentration (4 mM) of potassium for each 24 h.  In non-pretreated conditions 
(Fig. 2A), aldosterone production at 24 h was reduced by candesartan treatment to 25% 
of the Ang II-induced levels.  This candesartan suppression was impaired after 13 days 
in culture; and aldosterone production was nearly restored to the levels of day 1 of 
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candesartan treatment by the 15th day of culture (Fig. 2A).  The phenomenon of 
impaired candesartan suppression was also detected in the cells pretreated with 
candesartan (Fig. 2B) as well as Ang II (Fig. 2C).  During the observation period, 
maximal suppression of aldosterone levels was seen between 7- to 9-day culture with 
candesartan.  The breakthrough phenomenon from candesartan effects on Ang 
II-induced aldosterone production was detected after 15-day culture conditions 
regardless of the pretreatment with Ang II and candesartan. 
To characterize the changes of Ang II sensitivity and the expression of 
steroidogenic enzymes in candesartan-treated H295R cells, levels of AT1R, StAR, 
P450scc and CYP11B2 mRNA were examined by real-time PCR analysis (Fig. 3).  
The expression levels of AT1R were not significantly changed by chronic candesartan 
treatment during 15-day culture, suggesting that downregulation of AT1R was not 
critical in the aldosterone breakthrough phenomenon.  After 1-day culture with Ang II, 
mRNA levels of StAR, P450scc and CYP11B2 were significantly increased.  
Co-treatment with candesartan for 1 day restored the Ang II-induced expression of 
steroidogenic factors including StAR and P450scc to the basal levels, while the 
CYP11B2 level was partially reversed by candesartan for 1 day (Fig. 3).  At the 7th day 
of culture, Ang II significantly induced StAR and CYP11B2 expression, which was 
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restored by candesartan treatment.  After 15 days of culture, Ang II induction of StAR 
and P450scc expression became insignificant, while Ang II augmentation of CYP11B2 
expression was persistent throughout the 15-day culture (Fig. 3).  Of note, candesartan 
treatment exerted significant suppression of Ang II-induced CYP11B2 mRNA levels on 
1- and 7-day culture; however, the inhibitory effects by candesartan were abolished by 
the 15th day of culture (Fig. 3).  Thus, the candesartan effects on reducing Ang 
II-induced CYP11B2 expression and Ang II-induced aldosterone synthesis were 
reversed during the course of candesartan treatment over a 15-day culture, i.e., a 
possible cellular aldosterone breakthrough was demonstrated in vitro. 
Based on our earlier study (12), BMP-6 enhances Ang II-induced aldosterone 
production through ERK1/2 signaling.  To investigate the involvement of BMP-6 in 
reducing aldosterone suppression therefore, aldosterone breakthrough by candesartan, 
we assessed the changes of ERK1/2 activation induced by Ang II in the presence and 
absence of candesartan and BMP-6.  As shown in Fig. 4, the stimulating effects of 
Ang II on ERK1/2 phosphorylation were blocked by candesartan treatment for 1-, 7- 
and 15-day culture.  In the presence of BMP-6, the Ang II-induced ERK1/2 
phosphorylation was enhanced and candesartan treatment was ineffective in suppressing 
Ang II-induced ERK1/2 phosphorylation for 1-, 7- and 15-day culture (Fig. 4).  These 
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results suggest that BMP-6 enhancement of Ang II-induced ERK1/2 activation is 
possibly involved in the mechanism of aldosterone breakthrough from chronic 
candesartan treatment in adrenocortical cells. 
We next examined changes of BMP-6 signaling in adrenocortical cells in the 
presence of Ang II and candesartan.  BMP-6-induced activation of Smad1,5,8 
phoshphorylation was detected by immunofluorescence (Fig. 5A) and Western 
immunoblot (Fig. 5B).  Nuclear localization of phospho-Smad1,5,8 proteins was 
detected in cells stimulated by BMP-6 for 1 h, and pretreatment with Ang II and 
candesartan for 24 h had no effect on the nuclear localization (Fig. 5A).  To investigate 
changes in the intensity of phospho-Smad1,5,8 signaling during 15-day culture, H295R 
pretreated with Ang II and candesartan for 1, 7 and 15 days were stimulated by BMP-6, 
and then cell lysates were used for immunoblotting analysis for phospho-Smad1,5,8 
detection after adjustment of total protein contents (Fig. 5B).  On 1-day culture, there 
were no differences in BMP-6 responsiveness between cells treated with Ang II and 
Ang II / candesartan cotreatment.  However, after 7 days of culture Smad1,5,8 
activation was impaired in Ang II-treated cells as compared to cells co-treated with Ang 
II / candesartan.  On 15-day culture, Ang II-treated cells had a weak response to 
exogenous BMP-6 stimulation compared with those treated with Ang II plus 
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candesartan (Fig. 5B).  To quantify BMP-6 signaling in H295R cells, a 
BMP-responsive reporter construct, BRE-luc, was utilized (Fig. 6).  BMP-6-induced 
BRE-luc activity was reduced in cells treated with Ang II for 15 days although it was 
not significantly changed by Ang II treatment for 1- and 7-day culture.  However, this 
reduction was not observed in cells co-treated with candesartan for 15 days (Fig. 6).  
Taken together with the results in Fig. 5B, it is likely that chronic Ang II treatment 
reduces BMP-6 signaling, whereas the co-treatment with candesartan abolishes Ang 
II-induced reduction of BMP-6-to-Smad1,5,8 signaling activity in adrenocortical cells. 
To examine the mechanism by which Ang II and candesartan treatment affects 
BMP-6 signaling pathway in H295R cells, the expression of key molecules for BMP-6 
actions in H295R cells were evaluated by quantitative PCR.  As shown in Fig. 7A, 
BMP-6 ligand expression appeared to be reduced in the course of 15-day Ang II 
treatment.  The reduction of BMP-6 was blocked by the addition of candesartan.  The 
expression of functional BMP-6 receptors, ActRII and ALK-2, was also reduced in cells 
treated with Ang II for 15 days, an effect that was attenuated in cells co-treated with 
candesartan (Fig. 7A).  ALK-3 expression was not affected by Ang II as well as 
candesartan treatment in H295R cells.  We also examined the Smad mRNA expression 
levels.  Based on our earlier data by cDNA array analysis (20), the predominant Smad 
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molecules expressed in H295R cells are Smad1, 4 and 5.  As shown in Fig. 7B, Ang II 
treatment had a moderate effect on reducing Smad1 and Smad5, but not Smad4, mRNA 
levels.  Unlike the results observed with respect to ActRII and ALK-2, co-treatment 
with candesartan had no significant effects on the expression level of Smad1,4 and 5 in 
cells treated with Ang II for 1, 7 or 15 days (Fig. 7B).  In addition, we examined 
effects of high concentrations of aldosterone (10 to 100 nM) on the expression levels of 
BMP-6 and its receptors ALK-2 and ActRII.  As shown in Fig, 7C, treatment with a 
high concentration of aldosterone (100 nM) transiently decreased BMP-6 and ActRII 
mRNA levels; however, the changes were restored by the time when aldosterone 
breakthrough occurs in H295R cells. 
To elucidate the functional roles of the BMP-6 system in the aldosterone 
breakthrough phenomenon, we attempted to ablate the endogenous BMP-6 signaling 
with a neutralizing antibody against BMP-6 ligand or extracellular domains (ECDs) of 
BMP type I receptors that harmlessly block BMP-6 binding to endogenous ALK-2 (12, 
19).  ALK-6-ECD was used as a negative control since ALK-6 was not expressed in 
H295R cells (12).  As shown in Fig. 8A, the escape phenomenon by candesartan 
effects was ameliorated on cultures for 13 days in the presence of ALK-2-ECD, 
whereas ALK-6-ECD had no significant effects on the breakthrough phenomenon.  In 
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addition, the neutralization of BMP-6 by BMP-6-IgG also attenuated the breakthrough 
phenomenon in contrast to the cells treated with control IgG (Fig. 8B).  Thus, 
endogenous BMP-6/ALK-2 system is possibly involved in the mechanism by which 
chronic candesartan treatment attenuates the suppression of Ang II-induced aldosterone 
production. 
As shown in Fig. 9, immunohistochemical staining demonstrated that BMP-6 
protein was broadly expressed in the adrenal cortex of 12-week-old male Wistar-Kyoto 
(WKY) rats.  Notably, BMP-6 expression was detected most strongly in the zona 
glomerulosa of adrenal cortex obtained from age-matched male spontaneously 
hypertensive rats (SHR).  This finding infers in vivo roles of BMP-6 in regulating 
aldosterone production as an autocrine/paracrine factor in the adrenal glomerulosa. 
 
DISCUSSION 
 
Aldosterone breakthrough is a state of sustained aldosterone synthesis in the 
adrenal during relative long-term treatment with ACE inhibitors (13, 14) and/or ARB 
(15, 23).  Based on literature reports (24), the incidence of the aldosterone 
breakthrough phenomenon ranges from 10% over 6 months to 53% over 1 year.  These 
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figures, however, depend on the definition of “aldosterone breakthrough” in the 
respective studies.  For example, in studies that defined breakthrough as any increase 
from individual basal levels of pre-ACEI and/or ARB treatment, the incidence is 
unexpectedly high ranging from 40 to 53% (24).  No specific association between 
variety or dose of ACE inhibitor and/or ARB and incidence of aldosterone breakthrough 
has been reported (25). 
Extraadrenal aldosterone production in the heart and blood vessels (26, 27) 
may also contribute to aldosterone breakthrough phenomenon.  Nevertheless, there is 
still an argument against the pathophysiological significance of local aldosterone 
because of its very low production (28).  It is therefore important to understand how 
the regulation of aldosterone synthesis in the adrenal cortex may be involved as a 
causative mechanism in aldosterone breakthrough.  We studied the mechanism of 
aldosterone breakthrough phenomenon in cultured adrenocortical cells.  Aldosterone 
breakthrough is clinically considered as an elevation of plasma aldosterone 
concentration after treatment with ACEI or ARB as compared to pretreatment values.  
In the present in vitro study, the significant impairment of ARB suppression on Ang 
II-induced aldosterone production was defined as the cellular breakthrough 
phenomenon. 
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We recently reported that BMP-6, which is expressed in adrenal cortex, 
enhances Ang II- but not potassium-induced aldosterone production in human 
adrenocortical H295R cells (12).  Molecular approaches have shown that BMP-6 
augments Ang II-induced aldosterone production by upregulating ERK1/2 signaling via 
receptor complexes composed of type I receptors including ALK-2 and/or ALK-3, and 
ActRII (12).  In the present study, reduction of ARB effects on Ang II-induced 
aldosterone production was also shown in adrenocortical cells in vitro.  Expression 
levels of AT1R mRNA were not directly involved in this phenomenon.  Notably, the 
enhancing effects of BMP-6 on Ang II-induced ERK1/2 signaling were resistant to 
ARB.  BMP-6-induced Smad1,5,8 activation was in turn amplified in cells chronically 
treated with Ang II plus an ARB, candesartan, compared with cells treated with Ang II 
alone.   
We have earlier reported that cellular BMP-6 mRNA expression was 
transiently reduced at 6 to 12 h after stimulation with Ang II and potassium in H295R 
cells, while it was not affected by treatments with ACTH and forskolin (20).  Since 
BMP-6 plays critical roles in the differential mechanisms regulating aldosterone 
production by Ang II and potassium through modulating Ang II-induced MAP kinase 
pathway (12), this autocrine regulation most likely contributes to fine-tuning 
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aldosterone production in the adrenal cortex.  In the present study we found that the 
expression of BMP-6 mRNA and its receptor mRNAs, including ALK-2 and ActRII, 
were decreased by long-term Ang II exposure but restored by co-treatment with ARB.  
In contrast, long-term exposure of aldosterone at high concentrations had no significant 
effects on the expression of BMP-6, ALK-2 and ActRII in adrenocortical cells.  
Importantly, neutralization of ALK-2 and BMP-6 function attenuated the escaping 
effect from aldosterone suppression by ARB.  Given that inhibition of endogenous 
BMP-6 by neutralizing antibodies selectively reduced Ang II- but not 
potassium-induced aldosterone synthesis (12), it is likely that endogenous BMP-6 plays 
an important autocrine role in regulating aldosterone production caused by Ang II.  
Changes in the bioavailability of BMP-6 and cellular BMP responsiveness may be, at 
least in part, involved in the occurrence of cellular escape from aldosterone suppression 
under chronic treatment with ARB (Fig. 10). 
Taken together, the presence of the breakthrough mechanisms cannot be 
explained solely by the effect of Ang II through the AT1R.  Factors that regulate 
aldosterone production other than Ang II and potassium have been suggested, which 
either stimulate (e.g. corticotrophin, prolactin, serotonin, vasopressin, endothelins) or 
inhibit (e.g. atrial natriuretic hormone; ANP, nitric oxide, somatostatin) circulating 
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aldosterone levels.  Among these factors, in vivo physiological significance has been 
only demonstrated for ACTH and ANP (29).  Since no significant changes in plasma 
cortisol concentrations during ACE inhibition are observed (30), it is likely that ACTH 
has little involvement in aldosterone escape during ACE inhibitor or ARB therapy.  
Potassium levels rather, than the renin-angiotensin system, stimulate aldosterone 
secretion during salt restriction (31).  However, no significant correlation between 
plasma aldosterone concentration and serum potassium concentration were shown in 
patients treated with long-term ACE inhibitor therapy (32).  Nevertheless, small 
changes in serum potassium concentration within the physiological range may affect 
aldosterone secretion. 
A possible role for Ang II action through AT2R is worthy of consideration to 
explain why ARB may not be effective in lowering plasma aldosterone concentration in 
all cases.  In this regard, Naruse et al. (15) reported that aldosterone breakthrough 
occurred during long-term ARB candesartan therapy in stroke-prone spontaneously 
hypertensive rats, and when they administered an AT2R antagonist concomitantly with 
candesartan, plasma aldosterone concentrations decreased significantly.  Ang II action 
in aldosterone synthesis is mediated solely by AT1R in H295R cells since AT2R is not 
expressed (33).  Regarding endothelins, the plasma endothelin-1 (ET-1) concentration 
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tends to be elevated in patients with chronic heart failure (34).  Since ET-1 stimulates 
aldosterone secretion and adrenocortical growth, it may also be a possible candidate 
involved in the mechanism of aldosterone breakthrough (35).  
Collectively, the existence of cellular aldosterone breakthrough was 
demonstrated in the current study.  In a clinical aspect, aldosterone breakthrough 
occurs in a significant proportion of patients on long-term ACE inhibitor and/or ARB 
therapy, which seems likely to be originated in the adrenocortical cells per se.  The 
renin-angiotensin-aldosterone (RAA) system is a key regulator of blood pressure and 
fluid homeostasis.  The main effector molecule of this system, angiotensin II, is 
produced from the substrate angiotensinogen through sequential enzymatic cleavages by 
renin and ACE.  In the circulating system, the amount of renin in the plasma is a key 
rate-limiting step determining the overall RAA system activity.  Since the activity of 
the circulating RAA system is precisely calibrated by signals from the kidney linked to 
blood pressure and intake of salt and water, the counter-regulatory stimuli to RAA 
system including elevated potassium levels, use of diuretics, decompensated heart 
failure, and declines in blood pressure may also be involved in the mechanism of 
aldosterone breakthrough. 
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Renin inhibitors suppress the RAA system in its earliest stage without 
accumulation of active precursor substances.  This new class of antihypertensive 
medication may, therefore, be associated with less aldosterone breakthrough than 
conventional RAA system blockade with ACEI and/or ARB (36).  The breakthrough 
phenomenon might be associated with important cardiovascular and renal outcomes, 
including left ventricular hypertrophy, poor exercise tolerance, refractory proteinuria, 
and declining glomerular filtration rate (24).  It is therefore important to characterize 
molecular cause of aldosterone breakthrough.  If aldosterone breakthrough is detected 
in the setting of stable potassium and salt balance, then the addition of aldosterone 
antagonists or renin inhibitors to conventional heart and kidney failure regimens could 
improve clinical outcomes. 
Based on the present in vitro study, changes in the bioavailability of BMP-6 
and cellular BMP responsiveness are, at least in part, involved in the occurrence of 
cellular escape from aldosterone suppression under chronic AT1 blockade.  Further 
approaches would be necessary to determine the factors that control BMP-6 expression 
in the adrenal and the pathophysiological roles of adrenocoritcal BMP-6 system in vitro 
in studying aldosterone breakthrough. 
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FIGURE LEGENDS 
 
Fig. 1. Effects of ARB treatment on Ang II-induced aldosterone production by 
H295R cells.  A) Dose-dependent suppression of aldosterone (Aldo) by 24-h treatment 
with Ang II and an ARB, candesartan (CV).  After preculture in 96-well plates (4 × 104 
viable cells), culture medium was replaced with fresh DMEM/F12 containing 4 mM of 
potassium and low (1%) concentration of FCS.  Cells were then treated with indicated 
concentrations of Ang II (nM) in the absence or presence of CV (0.3 to 10 nM) for 24 h.  
Aldo levels in the conditioned medium were determined by radioimmunoassay.  
Results are shown as mean ± SEM of data from each performed with triplicate samples.  
*, P < 0.05 and **, P < 0.01 vs. the group of CV = 0 nM at each Ang II concentration;  
#, P < 0.01 vs. group of Ang II = 0 nM.  B) Long-term effects of CV on Ang 
II-induced Aldo accumulation.  Cells were treated with Ang II (10 nM) in the absence 
or presence of CV (IC50 = 1.0 nM) and Aldo levels were determined in the conditioned 
medium accumulated for 1 to 15 days.  The percent CV suppression of Ang II-induced 
Aldo levels was shown during the culture.  Results are shown as mean ± SEM of data 
from at least three separate experiments, each performed with triplicate samples.  Bars 
with different letters indicate that group means are significantly different at P < 0.05. 
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Fig. 2. Long-term effects of ARB on Ang II-induced aldosterone secretion.  After 
preculture in 96-well plates (4 × 104 viable cells) cells were pretreated with an ARB, 
candesartan (CV; 1.0 nM; B) or Ang II (10 nM; C) for 3 days.  To determine 24-h 
production of aldosterone (Aldo), culture medium was completely replaced with fresh 
DMEM/F12 containing 4 mM of potassium, 1% FCS and Ang II (10 nM) in the absence 
or presence of CV (1.0 nM) every 24 h, and then Aldo levels for 24-h culture medium 
was determined by radioimmunoassay.  Results are shown as mean ± SEM of data 
from at least three separate experiments, each performed with triplicate samples.  *, P 
< 0.05 and **, P < 0.01 vs. Day 1 values of Ang II + CV groups or between the 
indicated groups. 
 
Fig. 3. Effects of Ang II and ARB treatment on AT1R, StAR, P450scc and 
CYP11B2 expression in H295R cells.  After preculture, cells were treated with Ang 
II (10 nM) in the absence or presence of an ARB, candesartan (CV; 1.0 nM) for 1, 7 and 
15 days in DMEM/F12 containing 4 mM of potassium and 1% FCS.  Total cellular 
RNA was extracted and subjected to RT reaction.  For the quantification of AT1R, 
StAR, P450scc and CYP11B2 mRNA levels, real-time PCR analysis was performed.  
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The expression levels of target genes were standardized by RPL19 level in each sample.  
Results are shown as mean ± SEM of data from at least three separate experiments, each 
performed with triplicate samples.  *, P < 0.05 and **, P < 0.01 as compared to each 
control group of Day 1, 7 and 15. 
 
Fig. 4. Effects of ARB on ERK1/2 phosphorylation induced by Ang II and BMP-6.  
After preculture, cells were pretreated with or without an ARB, candesartan (CV; 1.0 
nM) for 1, 7 and 15 days, and then cells were stimulated with Ang II (10 nM) and 
BMP-6 (100 ng/ml) in serum-free DMEM/F12 containing 4 mM of potassium.  After 
the stimulation for 60 min, cells were lysed and subjected to SDS-PAGE and 
immunoblotting analysis using anti-pSmad1,5,8, anti-pERK1/2 and anti-tERK1/2 
antibodies.  Results shown are representative of those obtained from three independent 
experiments. 
 
Fig. 5. Effects of Ang II and ARB on Smad1,5,8 phosphorylation in H295R cells.  
A) Cells were treated with Ang II (10 nM) and an ARB, candesartan (CV; 1.0 nM) for 1 
h and the cells were stimulated with BMP-6 (100 ng/ml) for 1 h in serum-free 
DMEM/F12 containing 4 mM of potassium.  Immunofluorescence studies were 
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performed with pSmad1,5,8 antibody.  B) Cells were pretreated with Ang II (10 nM) 
and CV (1.0 nM) for 1 to 15 days and then stimulated with BMP-6 (100 ng/ml) for 1 h 
and 3 h in serum-free DMEM/F12 containing 4 mM of potassium.  Total cell lysates 
were subjected to evaluate Smad1,5,8 phosphorylation by Western immunoblotting 
analysis.  Results shown are representative of those obtained from three independent 
experiments. 
 
Fig. 6. Long-term effects of Ang II and ARB on BMP-6 signaling in H295R cells.  
Cells were pretreated with Ang II (10 nM) and an ARB, candesartan (CV; 1.0 nM) for 1 
to 15 days, and then transiently transfected with a BMP-responsive reporter construct, 
BRE-Luc plasmid (500 ng) and pCMV-β-gal.  The cells were then treated with BMP-6 
(100 ng/ml) for 24 h in DMEM/F12 containing 4 mM of potassium and 1% FCS.  The 
cells were washed with PBS, lysed and the luciferase activity and β-galactosidase 
(β-gal) activity were measured by luminometer.  The data were analyzed as the ratio of 
luciferase to β-gal activity.  Results are shown as mean ± SEM of data from at least 
three separate experiments, each performed with triplicate samples.  *, P < 0.05 and 
**, P < 0.01 vs. each control group or between the indicated groups. 
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Fig. 7. Effects of Ang II, ARB and aldosterone on BMP-6, BMP-6 receptor and 
Smads expression.  A), B) After preculture, cells were treated with Ang II (10 nM) in 
the absence or presence of an ARB, candesartan (CV; 1.0 nM) for 1, 7 and 15 days in 
DMEM/F12 containing 4 mM of potassium and 1% FCS.  Total cellular RNA was 
extracted and subjected to RT reaction.  For the quantification of A) BMP-6, ALK-2, 
ALK-3, ActRII, and B) Smad1, 4 and 5 mRNA levels, real-time PCR analysis was 
performed.  C) Cells were treated with aldosteone (Aldo; 10 and 100 nM) for 1, 7 and 
15 days in DMEM/F12 containing 4 mM of potassium and 1% FCS, and then total 
cellular RNA was subjected to RT reaction and real-time PCR for the quantification of 
BMP-6, ALK-2 and ActRII.  The expression levels of target genes were standardized 
by RPL19 level in each sample.  Results are shown as mean ± SEM of data from at 
least three separate experiments, each performed with triplicate samples.  *, P < 0.05 
and **, P < 0.01 vs. each control group or between the indicated groups. 
 
Fig. 8. Effect of neutralization of ALK-2 and BMP-6 on the aldosterone 
breakthrough phenomenon.  After preculture in 96-well plates (4 × 104 viable cells) 
with fresh DMEM/F12 containing 4 mM of potassium and 1% FCS, cells were treated 
with Ang II (10 nM) and an ARB, candesartan (CV; 1.0 nM) for 7 to 13 days.  Cells 
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were then treated with A) extracellular domains (ECDs; 1.0 µg/ml) that lack 
transmembrane and intracellular domains of ALK-2 or ALK-6; and B) anti-BMP-6 
neutralizing IgG (1.0 µg/ml) or control IgG (1.0 µg/ml) for 24 h before each collection 
of the conditioned medium.  Results are shown as mean ± SEM of data from at least 
three separate experiments, each performed with triplicate samples.  Bars with ‘a’ and 
‘b’ indicate significant difference from each control (Ang II group) level at P < 0.05; 
and the bars with different letters indicate that group means are significantly different at 
P < 0.05. 
 
Fig. 9. Expression of BMP-6 protein in rat adrenal cortex.  A) Control study for 
immunohistochemistry in the adrenal cortex sections derived from 12-week-old male 
Wistar-Kyoto (WKY) rats.  Normal goat antibody (control antibody) was used for 
primary antibody instead of anti-BMP-6 antibody.  B) Immunohistochemical study 
revealed that BMP-6 protein is expressed in the adrenal cortex derived from 
12-week-old male WKY rats and age-matched spontaneously hypertensive rats (SHR).   
It is of note that BMP-6 protein expression was densely detected in the zona 
gromerulosa of adrenal cortex of SHR.  Bars indicate 30 µm in size. 
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Fig. 10. Possible involvement of BMP-6 in aldosterone breakthrough in 
adrenocortical cells.  1) BMP-6 signaling supports Ang II-induced aldosterone 
synthesis by sustaining Ang II-induced ERK1/2 phosphorylation.  2) Cellular 
expression of BMP-6, the receptor (ALK-2 and ActRII) and Smad1,5,8 activation were 
downregulated by long-term Ang II exposure.  3) However, in the presence of 
co-treatment with ARB, the activation of BMP-6 signaling is maintained, which may 
lead to aldosterone breakthrough phenomenon in vitro. 
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